Clinical Trials Browser

Phase 2 × Cisplatin × Genitourinary × Clear all

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT03609216 2026-03-04

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2 Recruiting

Infiltrating Bladder Urothelial Carcinoma

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT03937843 2026-01-20

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2 Active not recruiting

Testicular Neoplasms, Seminoma

NCT07296705 2025-12-22

HARBOR

Phase 2 Recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT06091124 2025-12-08

NEOBLAST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07184021 2025-09-19

No Acronym

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06571708 2025-09-02

NeoSTOP-IT

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06983210 2025-08-14

GRAPE

Phase 2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01261728 2025-08-08

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Phase 2 Completed

Carcinoma, Transitional Cell

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03093922 2025-04-22

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT06415318 2025-04-22

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Phase 2 Recruiting

Penile Neoplasms

NCT06257017 2025-04-04

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Phase 2 Completed

87 enrolled 13 charts

Metastatic Bladder Urothelial Carcinoma

NCT02662062 2025-01-27

PCR-MIB

Phase 2 Completed

28 enrolled 15 charts

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT00981656 2024-09-19

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Phase 2 Completed

37 enrolled 19 charts

Urinary Bladder Neoplasms

NCT02177695 2024-09-19

COXEN

Phase 2 Completed

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

Phase 2 Not yet recruiting

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

Locally Advanced Prostate Cancer

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT06309732 2024-03-13

GAMEC-II

Phase 2 Completed

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Terminated

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT05877911 2023-05-26

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy

Phase 2 Unknown

GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Acute Kidney Injury

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Phase 2 Unknown

Urothelial Carcinoma Bladder

NCT01524991 2022-07-11

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 2 Completed

36 enrolled 12 charts

Carcinoma, Transitional Cell

NCT00777491 2022-06-15

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Phase 2 Completed

70 enrolled 18 charts

Urinary Bladder Neoplasms

NCT04475016 2022-06-09

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Phase 2 Completed

Penile Neoplasms

NCT03294304 2021-12-16

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Phase 2 Completed

43 enrolled 20 charts

Urinary Bladder Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT03051373 2021-08-09

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Phase 2 Completed

Carcinoma, Transitional Cell

NCT00006111 2021-02-21

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00514540 2020-09-01

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2 Completed

121 enrolled 8 charts

Prostatic Neoplasms

NCT01277744 2020-01-13

Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 2 Completed

22 enrolled 7 charts

GenitourinarySarcoma

Wilms Tumor, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT00003400 2019-11-04

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT01589094 2019-10-02

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Phase 2 Completed

51 enrolled 11 charts

Urinary Bladder Neoplasms